At the same time, it is important to note that there remain certain favorable European LeukemiaNet disease subsets, such as core-binding factor AML, NPM1-mutated AML, and FLT3 wildtype AML, wherein finite duration of induction and consolidation therapy such as 3 + 7 with or without GO, fludarabine–Ara-C–filgrastim (FLAG), or FLAG-GO (±idarubicin) may be curative, with long-term remissions in >70–75% of patients50–53. The gene discussed is FLT3; the disease is acute myeloid leukemia.